Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis
Authors' conclusion
In this study, improvements in various measures, including ALT, the FIB-4 index, GGT and albumin, were observed with SGLT2is compared with DPP4is, suggesting that SGLT2is may provide hepatoprotective benefits, including the prevention of liver fibrosis, in patients with T2D in Japan.
Study context
- Population
- Patients with T2D in Japan newly treated with an SGLT2i or a DPP4i, RWD Database (1 January 2015 to 24 September 2021)matched cohort
- Participants
- 955 vs 3,063
- Exposure
- SGLT2i vs DPP4i
- SGLT2in = 955
- DPP4in = 3,063reference
- Outcome
- Change from baseline in ALT
- Follow-up
- 1 year after the index date
Methodological detailspropensity-score matched 1:4 (SGLT2i:DPP4i), real-world database
- Propensity-score matched 1:4 (SGLT2i:DPP4i)
- Real-world database
Main finding
As reported in the abstract
1 year
- Significantly greater reduction in ALT with SGLT2i vs DPP4i
- Matched cohort
- Welch's t-test
Observational data: associations, not effects.
Secondary outcomes
FIB-4 index, gamma-glutamyl transpeptidase (GGT) and albumin
- Significantly greater reductions in FIB-4 index and GGT and significantly greater increase in albumin with SGLT2i vs DPP4i
Change in ALT by subgroup
- Significantly greater change in ALT with SGLT2i vs DPP4i among subgroups with lower baseline FIB-4 index and HbA1c
Original publication
Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis. Diabetes Obes Metab. Published 12 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →